TABLE 1.
Patient demographics and aneurysm characteristics.
| No./Ave (range) | %/Stdev | |||||
| Treatment group | Control group | Treatment group | Control group | OR (95% confidence interval) | P Value | |
| Patients | 42 | 36 | ||||
| Age | 47.9 (10–71) | 50.6 (28–69) | ±15.0 | ±9.4 | 1.017 (0.981–1.055) | 0.355 |
| Female sex | 8 | 3 | 19.9% | 8.3% | 1.545 (0.242–9.850) | 0.353 |
| Hypertension | 19 | 19 | 45.2% | 52.8% | 1.289 (0.522–3.186) | 0.582 |
| Diabetes | 3 | 2 | 7.1% | 5.6% | 0.608 (0.091–4.049) | 0.607 |
| Presentation | 0.425 | |||||
| Incidental | 7 | 10 | 16.7% | 27.8% | ||
| Non-specific symptoms∗ | 8 | 1 | 19.0% | 2.8% | ||
| Stroke | 7 | 11 | 16.7% | 30.6% | ||
| SAH | 1 | 3 | 2.4% | 8.2% | ||
| Mass effect | 19 | 11 | 45.2% | 30.6% | ||
| Aneurysms | 44 | 39 | ||||
| Size (mm) | ||||||
| Large (10–25) | 36 | 28 | 81.8% | 71.8% | 1.341 (0.481–3.742) | 0.575 |
| Giant (>25) VBD^ | 9 7 | 10 12 | 18.2% 15.9% | 28.2% 30.8% | 2.349 (0.817–6.753) | 0.113 |
| Location | 0.893 | |||||
| LVA | 16 | 14 | 36.4% | 35.9% | ||
| RVA | 21 | 20 | 47.7% | 51.3% | ||
| BA | 5 | 5 | 11.4% | 12.8% | ||
| VBJ | 2 | 0 | 4.5% | 0% | ||
| Branch# | 0.320 | |||||
| AICA | 4 | 2 | 9.1% | 5.1% | ||
| PICA | 21 | 11 | 47.7% | 28.2% | ||
| VA | 1 | 0 | 2.3% | 0% | ||
| NO | 18 | 26 | 40.9% | 66.7% | ||
| Therapy modality | ||||||
| Stents & alone | 31 | 11 | 70.5% | 28.2% | ||
| Stents & +coils | 13 | 28 | 29.5% | 71.8% | 0.165 (0.064–0.427) | <0.001 |
| Number of devices implanted | 52 (1.2,1–4) | 75 (1.9,1–4) | <0.001 | |||
| 1 | 38 | 14 | 86.4% | 35.9% | ||
| 2 | 5 | 16 | 11.4% | 41.0% | ||
| 3 | 0 | 7 | 0% | 18.0% | ||
| 4 | 1 | 2 | 2.2% | 5.1% | ||
∗The symptoms without association with lesions confirmed by computerized tomography (CT) and/or magnetic resonance imaging (MRI); VBD^, vertebrobasilar dolichoectatic aneurysms.#The branch arteries affected by lesions or covered by stents; &Stents refers to PEDs and conventional stents (Neuroform, Enterprise, Solitaire and Lvis).